Relating to step therapy protocols and interchangeable biosimilars

Where it is now

1. ✓
   Done: IntroducedFebruary 15, 2023
2. ✓
   Done: SubcommitteeFebruary 21, 2023
3. ✕
   Stopped: Senate committeeDied when the General Assembly ended
4. Next: Passes the Senate
5. Next: House committee
6. Next: Passes the House
7. Next: To the Governor
8. Next: Signed into law

Died when the session ended The General Assembly adjourned on April 19, 2024. Bills that didn’t pass both chambers died. What’s a funnel?

What’s in it

This bill relates to step therapy protocols and interchangeable biosimilars. Under current law, a health carrier, health benefit plan, or utilization review organization may require a covered person (person) to try a prescription drug (drug) with the same generic name and demonstrated bioavailability, or a biological product that is an interchangeable biological product, prior to providing coverage for an equivalent branded drug. The bill allows a health carrier, health benefit plan, or utilization review organization to also require a person to try an interchangeable biosimilar prior to providing coverage for an equivalent branded drug. “Biosimilar” and “interchangeable” are defined in the bill.

From the explanation printed with the bill as introduced, written by the Legislative Services Agency. Amendments adopted later aren’t reflected. Full bill text

Senate subcommittee

Named February 21, 2023. On February 23, 2023 it recommended indefinite postponement. [].

• Sen. Kevin Alons REmail
• Sen. Janet Petersen DEmail
• Sen. Annette Sweeney REmail

Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part

Iowa Code it changes

Amends§514F.7

Read from the bill as introduced. Each links to every bill touching that chapter of the Iowa Code. How the Code works